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Summary
 
We have analyzed the presence of immature and mature dendritic cells (DCs) within adenocar-
cinoma of the breast using immunohistochemistry. Immature DCs were defined by expression of
CD1a-, Langerin-, and intracellular major histocompatibility complex class II–rich vesicles.
Mature DCs were defined by expression of CD83 and DC-Lamp. Breast carcinoma cells were
defined by morphology and/or cytokeratin expression. We demonstrate two levels of hetero-
geneity of DCs infiltrating breast carcinoma tissue: (a) immature CD1a
 
1 
 
DCs, mostly of the
Langerhans cell type (Langerin
 
1
 
), were retained within the tumor bed in 32/32 samples and (b)
mature DCs, CD83
 
1
 
DC-Lamp
 
1
 
, present in 20/32 samples, are confined to peritumoral areas.
The high numbers of immature DCs found in the tumor may be best explained by high levels
of macrophage inflammatory protein 3
 
a
 
 expression by virtually all tumor cells. Confirming the
immature/mature DC compartmentalization pattern, in vitro–generated immature DCs adhere
to the tumor cells, whereas mature DCs adhere selectively to peritumoral areas. In some cases,
T cells are clustering around the mature DCs in peritumoral areas, thus resembling the DC–T cell
clusters of secondary lymphoid organs, which are characteristic of ongoing immune reactions.
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D
 
endritic cells (DCs)
 
1
 
 constitute a complex system of
cells uniquely able to induce primary immune responses
(1–4). DC progenitors in the bone marrow give rise to cir-
culating precursors that home to the tissue, where they re-
side as immature cells with high phagocytic capacity. Upon
tissue damage, DCs capture Ag and subsequently migrate
to the lymphoid organs, where they select rare Ag-specific
T cells, thereby initiating immune responses. During migra-
tion and within the secondary lymphoid organs, DCs un-
dergo maturation from Ag-capturing cells to APCs. DCs
present Ag to CD4
 
1
 
 T cells (5), which in turn regulate the
immune effectors, including Ag-specific effectors such as
CD8
 
1
 
 T cells and B cells as well as nonspecific effectors
such as macrophages, eosinophils, and NK cells.
It is currently believed that three subsets of human DCs
exist: two of myeloid origin and one of lymphoid origin.
These subsets differ with respect to their biological func-
tion. Whereas both myeloid subsets, i.e., epidermal Langer-
hans cells (LCs) and interstitial (dermal) DCs (intDCs), in-
duce the proliferation of naive T cells, only intDCs are able
to induce the differentiation of naive B cells in vitro (6, 7).
Furthermore, in contrast to LCs, intDCs display potent and
long-lasting phagocytic capacity (7). DC subsets can also
skew Th responses toward either the Th1 or Th2 pathway.
DCs derived from CD14
 
1
 
 blood precursors were thus found
to induce Th1 differentiation (8). On the contrary, DCs
derived from lineage-negative CD4
 
1
 
IL-3R
 
a
 
1
 
 plasmacy-
toid precursors induce Th2 polarization, further strengthen-
ing the notion of functional heterogeneity between DC
subsets (8, 9).
Tumor immunity can be viewed as a three-step process
that includes (i) presentation of tumor-associated Ags (TAAs),
(ii) selection and activation of TAA-specific T cells as well
as non-Ag–specific effectors, and (iii) homing of TAA-spe-
cific T cells to the tumor site and elimination of tumor cells
(10–13). Tumors may escape immune surveillance due to
alterations at each of these steps. Thus, by release of factors
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 DCs, dendritic cells; HPCs, hematopoietic
progenitors; int, interstitial; LCs, Langerhans cells; MIP, macrophage in-
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such as IL-6, IL-10, M-CSF, and vascular endothelial growth
factor, tumors can prevent DC differentiation and/or APC
function (14, 15). Indeed, tumor-associated DCs are usu-
ally of a low allostimulatory capacity, particularly if isolated
from the progressing metastatic lesions, as in malignant
melanoma or blood from patients with advanced breast
cancer (16–18).
Recent findings challenge the concept that breast cancer is
a “nonimmunogenic” tumor: (a) T cells and antibodies spe-
cific for breast cancer–associated Ags, such as her-2/neu and
cdr2, have been detected in some patients (19–21), and (b)
tumor-infiltrating lymphocytes from breast cancer tissue give
rise to T cell lines responsive to autologous tumor (22).
Given the pivotal role of DCs in the induction of im-
munity, surprisingly few studies have addressed the in situ
status of DCs in breast carcinoma with immature CD1a
 
1
 
DCs observed in close association with tumor cells (23–25).
The conceptual progress in the field of DC physiology and
the availability of novel markers differentiating DC subsets
have led us to reevaluate DC infiltration in breast carcinoma
tissue. Here, we report two levels of heterogeneity of DCs
infiltrating breast carcinoma tissue: first, immature DCs,
mostly of the LC type, are retained in all samples within the
tumor beds; second, mature DCs, when present, are con-
fined to peritumoral areas.
 
Materials and Methods
 
Patient Characterization and Sample Acquisition.
 
Tissue samples
obtained at surgery were immediately embedded in OCT and
then frozen and stored at 
 
2
 
80
 
8
 
C until further processed. All tu-
mor samples were received as coded specimens, and for patient
confidentiality, numbers corresponding to the order received in
the laboratory were assigned. Nine normal breast specimens were
processed in the same way. The material was collected under the
auspices of Institutional Review Board protocol 97-79. The 32
studied cases of breast carcinoma, graded according to Bloom and
Richardson, were distributed as follows: ductal carcinoma, high
grade III (DC III),
 
 n 
 
5 
 
17; ductal carcinoma, intermediate grade II
(DC II),
 
 n 
 
5 
 
9; ductal carcinoma, low grade I (DC I),
 
 n 
 
5 
 
1;
mixed lobular carcinoma,
 
 n 
 
5 
 
3; carcinoma in situ,
 
 n 
 
5 
 
2. Ap-
proximately one-half of the cases presented with metastases to re-
gional lymph nodes. Patients’ ages at the time of diagnosis ranged
from 23 to 75 yr. See Table I for clinicopathological parameters
of each case, including age, tumor histological grade, tumor size,
lymph node involvement, lymphatic and vascular invasion, estro-
gen and progesterone receptor status, proliferation index using
Ki67 antibody MIB-1, DNA ploidy, and S phase.
 
Immunohistochemistry and Immunofluorescence.
 
Samples were snap
frozen, and serial 5-
 
m
 
m-thick sections were cut. Immunohis-
tochemical staining of acetone-fixed sections was performed by in-
cubation with mAbs recognizing the following molecules: CD1a
(IgG2a) and HLA-DR (IgG2a) (DAKO Corp.), Langerin/DCGM4
(IgG1) and DC-Lamp (IgG1) (generated at Schering-Plough Lab.;
reference 26), and CD83 (IgG2b), CD80 (IgG1), CD11c (IgG1),
CD3 (IgG1), CD4 (IgG1), CD8 (IgG1) (all from Coulter-Immuno-
tech), and CD86 (IgG1; Binding Site), followed by biotinylated goat
anti–mouse IgG (DAKO Corp.) and streptavidin–peroxidase (Vec-
tor Labs.). The peroxidase was developed by diaminobenzidene
tetrahydrochloride (brown color; Vector Labs.), and Mayer hema-
 
toxylin (Sigma Chemical Co.) was used as counterstain. In double-
step immunohistochemical staining, after an initial blocking with
goat serum and BSA, primary antibodies to CD83 or CD11c were
followed by goat biotinylated anti–mouse IgG2b, IgG1 (Coulter Im-
munology), and streptavidin–peroxidase. After another blocking for
endogenous biotin with avidin–biotin (Vector Labs.) and BSA, in a
secondary step, mAbs to CD4 or DC-Lamp were followed by bio-
tinylated anti–mouse IgG1 (Coulter Immunology) and streptavidin–
alkaline phosphatase (Vector Labs.). Rabbit anti–human CD3
(DAKO Corp.) was followed by swine biotinylated anti–rabbit IgG
(DAKO Corp.) and streptavidin–alkaline phosphatase. Peroxidase
was developed by 3-amino-9 ethylcarbazole (red color; Vector
Labs.), and alkaline phosphatase was revealed using Fast Blue as a
chromogen (blue color; Vector Labs.). Isotype-matched antibodies
(DAKO Corp.) were used as control. For the evaluation of mac-
rophage inflammatory protein (MIP)3
 
a
 
 staining, goat polyclonal
antibody to MIP3
 
a
 
 (R & D Systems, Inc.) was used, followed by
biotinylated goat anti–mouse IgG (DAKO Corp.) and biotinylated
rabbit anti–goat IgG (DAKO Corp.) and developed using strepta-
vidin–peroxidase (Vector Labs.).
For immunofluorescence, incubation with primary antibodies
to CD1a and DC-Lamp was followed by FITC-conjugated goat
antibodies to mouse Igs (Molecular Probes, Inc.). In a subsequent
secondary step, the rabbit polyclonal anticytokeratin antibody
(DAKO Corp.) was followed by biotinylated anti–rabbit IgG
(DAKO Corp.) and revealed by streptavidin–Texas Red (Molec-
ular Probes, Inc.). Isotype-matched antibodies were used as a con-
trol. Confocal laser scanning microscopy was performed along the
x–y axis with a confocal laser scanning microscope (TCS-SP; Leica
Inc.) equipped with 20, 40, and 100
 
3
 
 oil objectives.
 
Histological Scoring and Analysis.
 
Each slide was examined on at
least two separate occasions by at least two individuals, including
two pathologists. All cell counts were performed using an Olympus
Ax-70 epifluorescence photomicroscope at a magnification of 400
(40
 
3
 
 objective and 10
 
3
 
 eyepiece). Cells displaying membrane
staining, cytoplasmic staining, nuclear counterstain, and appropriate
morphology were included. The area counted in each section was
chosen randomly from a representative field of tumor. For each sec-
tion, three areas were assessed, and the counts are expressed as the
mean number of cells per high power field. In each case, a serial he-
matoxylin and eosin section was examined for orientation and con-
firmation of the histological diagnosis. Each case was scored blindly
with respect to patient history, presentation, and previous scoring.
 
Generation of DCs.
 
DCs were generated from CD34
 
1
 
 hemato-
poietic progenitors (HPCs) or from CD14
 
1
 
 blood precursors as
described previously (6). In brief, cord blood CD34
 
1
 
 HPCs were
cultured with GM-CSF (50 ng/ml; Schering-Plough Lab.), stem
cell factor (20 ng/ml; Amgen) and TNF (12.5 ng/ml; Genzyme
Corp.). DCs were harvested at the stage of immature precursor
and used either as a total population or after sorting of CD1a
 
1
 
CD14
 
2
 
 cells on day 7 of culture.
Monocyte-derived DCs were generated by culturing adherent
fraction of PBMCs with GM-CSF (100 ng/ml; Schering-Plough
Lab.) and IL-4 (50 ng/ml; Genzyme Corp.) (27–29). DCs were
used on day 7 either as immature CD1a
 
hi
 
CD83
 
2
 
HLA-DR
 
int
 
 or
after 48 h of activation with CD40 ligand as mature CD1a
 
lo
 
CD83
 
1
 
HLA-DR
 
hi
 
 cells.
 
In Situ Binding Assay.
 
We have used an adapted version of the
Stamper-Woodruff assay measuring binding of the lymphocytes
to endothelium (see Fig. 3). Immature DCs labeled with CD1a–
FITC or mature DCs labeled with HLA-DR–FITC were overlaid
onto frozen sections of breast carcinoma and allowed to adhere for
1 h. After stringent washing, tissue sections were indirectly stained 
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for cytokeratin expression. Raji cells were used as a negative con-
trol. Binding of DCs to breast carcinoma sections was quantitated
in several ways to establish the pattern of cell adherence. First, we
determined the density of immature and mature DCs adhering to
the breast cancer section at the tumor and stromal site, respec-
tively. Density values were based on the number of FITC-labeled
DCs that adhered per 0.2 mm
 
2
 
 (40
 
3
 
 objective, high power
field). For each section, three areas were assessed (see Table III).
Counting the number of DCs that were collected during the
washing procedure permitted us to estimate that 
 
z
 
15% of DCs
remained on the tissue section.
 
RNA Isolation and Reverse Transcriptase–PCR.
 
RNA was pre-
pared from fragments of tumor samples that were snap frozen and
stored at 
 
2
 
80
 
8
 
C until use using acidified phenol procedure ac-
cording to the manufacturer’s instructions (GIBCO BRL). RNA
preparations were treated with RNase-free DNase (37
 
8
 
C for 30 min;
Boehringer-Mannheim), digested with proteinase K in 1% SDS,
extracted with phenol-chloroform, and precipitated with ethanol.
RNA from tonsils was used as positive control. The following
primers were used: 
 
b
 
-actin, 5
 
9
 
-CTCCTTAATGTCACGCACG-
ATTC-3
 
9
 
 forward and 5
 
9
 
-GTGGGGCGCCCCAGGCACCA-3
 
9
 
reverse; MIP3
 
a
 
, 5
 
9
 
-TTGCTCCTGGCTGCTTTG-3
 
9
 
 forward
 
Table I.
 
Clinicopathological Characteristics of Patients
 
Patient Age
Tumor
type/grade
Tumor
size
Lymph node
metastasis
Lymphatic
invasion
Vascular
invasion
Estrogen
receptor
Progesterone
receptor MIB-1 DNA index/ploidy S phase
 
yr cm % %
 
1 54 DCIII 6 8/10
 
12 1 1
 
ND 0.9/Hypodiploid 5.1
2 55 CIS 11 0/11
 
22
 
ND ND ND ND ND
3 35 DCIII 6 0/13
 
22 2 2
 
20 1.8/Aneuploid 7.7
4 58 DCIII 8 0/17
 
22
 
ND ND ND ND ND
5 57 DCIII 4.5 2/21
 
22
 
ND ND ND ND ND
6 59 MLC 2.5 1/14
 
12
 
ND ND ND ND ND
7 62 DCIII 9 0/16
 
22 2 2
 
ND 1.6/Aneuploid 5.3
8 50 DCIII 2.5 0/21
 
12 1 2
 
50 1.9/Aneuploid ND
9 23 DCIII 9.1 0/11
 
11 2 2
 
90 ND ND
10 74 DCIII 5 5/15
 
12 1 2
 
ND 1.8/Aneuploid 7.5
11 64 DCIII 3.7 11/14
 
11 2 2
 
90 1.0/Diploid 3.3
12 50 DCIII 2.5 2/22
 
12 2 2
 
ND 1.6/Aneuploid 9.5
13 56 DCII and LC 3 3/17
 
22 1 1
 
10 1.0/Diploid 3.0
14 72 MLC 2 0/29
 
22 1 1
 
ND 1.0/Diploid 1.3
15 47 DCIII 2.4 1/18
 
22 2 2
 
ND 1.9/Tetraploid 14.5
16 52 DCII 3.2 0/17
 
22 1 1
 
ND 3.3/Hypertetraploid 8.9
17 56 DCIII 2.7 0/18
 
11 2 2
 
ND 1.0/Diploid 6.0
18 39 DCII ND 1/34
 
22 1 1
 
ND 1.8/Aneuploid 6.0
19 63 DCIII 4.2 8/18
 
12 2 2
 
ND 1.5/Aneuploid 21.1
20 66 DCII 8 0/14
 
22 1 1
 
ND 1.6/Aneuploid 10.6
21 39 DCIII 2.2 1/26
 
22 2 2
 
60–70 ND ND
22 38 DCIII 3.8 1/19
 
12 1 1
 
ND 1.0/Diploid 6.7
23 64 MLC 5 33/43
 
12 1 1
 
10 ND ND
24 60 DCIII 7.5 0/0
 
12 2 2
 
ND 2.6/Hypertetraploid 30
25 45 DCI 0.8 0/3 hot LN
 
12 1 1
 
5N D N D
26 60 DCII 1.5 5/7
 
12 1 1
 
40 ND ND
27 75 DCII and LC 1.5 3/23
 
12 1 1
 
5–10 ND ND
28 54 DCIII 7.0 2/4
 
12 2 2
 
15 2.1/Tetraploid 13.2
29 59 DCII 6.5 4/9
 
22 1 1
 
20 ND ND
30 35 CIS 5.7 ND
 
22 1 1
 
30 ND ND
31 44 DCII 4 2/9
 
22 1 1
 
10 ND ND
32 72 DCII 5 1/14
 
22 1 1
 
20 ND ND
Histopathological diagnosis of breast carcinoma: CIS, carcinoma in situ; DC, ductal carcinoma; LC, lobular carcinoma; MLC, multifocal lobular car-
cinoma.
Positive (
 
1
 
) and negative (
 
2
 
) findings. 
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and 5
 
9
 
-ACCCTCCATGATGTGCAAG-3
 
9
 
 reverse; MIP3
 
b
 
,
5
 
9
 
-CTGCTGGTTCTCTGGACTTC-3
 
9
 
 forward and 59-CACA-
CTCACACTCACAACAACAC-39 reverse. PCR was performed
in 35 cycles: 948C for 1 min, 558C for 1.5 min, and 728C for 1.5 min.
Results
We have analyzed the differentiation/maturation status
of DCs in frozen sections obtained from 32 patients with
adenocarcinoma of the breast using immunohistochemis-
try. The patients’ characteristics and clinicopathological pa-
rameters are given in Table I. Breast carcinoma cells were
identified by morphology and cytokeratin expression.
Immature DCs Are Present within the Tumor. Immature DCs
were characterized by CD1a expression, and the LC subset
was characterized by expression of Langerin/DCGM4 (Lang),
a recently identified Ag uniquely expressed within LCs (30).
In all samples, CD1a1 cells with dendritic morphology were
found to infiltrate the tumor beds (Fig. 1 a). The number of
CD1a1 immature DCs per high power field (4003) ranged
from 1 to 48 cells, with mean and median numbers 12 and 7,
respectively (Table II). Although a majority of DCs were
CD1a1Lang1 LCs, CD1a1Lang2 cells were also found.
The immaturity of CD1a1 DCs present within the tumor
was further demonstrated by the presence of MHC class II
intracellular compartments, as assessed by serial sectioning
in confocal microscopy in all CD1a1 DCs examined (Fig.
2 a). Normal breast tissue, i.e., that not infiltrated by tu-
mor, rarely displayed CD1a cells, and five of nine sections
were negative, whereas four of nine sections showed less than
Figure 1. In breast carcinoma tissue, immature DCs are intratumoral, whereas mature DCs and T cells are peritumoral. Immunofluorescence and im-
munohistochemistry of frozen sections of breast carcinoma tissue. Breast carcinoma is defined by indirect staining with anticytokeratin antibody (red) or
by morphology. Immature DCs were identified by labeling with CD1a mAb, mature DCs were identified by labeling with CD83 or DC-Lamp mAb,
and T cells were labeled using CD3 or CD4 mAb. (a) Immature, CD1a1 DCs (green) are retained within the tumor bed (403). Representative of 32
samples (patient 17). (b) In the normal mammary epithelium, CD1a staining is seldom detected. (c) Mature, DC-Lamp–labeled DCs (green) are selec-
tively localized in peritumoral areas (203). Pattern representative of 25 samples (patient 11). (d) No mature DCs, as judged by lack of CD83 staining, are
present in the normal breast tissue. (e) CD41 T cells (blue) cluster around CD831 mature DCs (red; 403) (patient 6). DC–T cell clusters were seen in
three out of five cases. (f) CD31 T cells (green) are spread within the peritumoral area. Representative of 19 cases (patient 11);in a majority of these cases,
T cells were CD81.1421 Bell et al.
three CD1a1 cells within the epithelial duct over the entire
section (Fig. 1). Thus, the presence of CD1a1 cells within the
breast cancer tissue was not solely due to its epithelial origin.
Mature DCs Are Localized in the Peritumoral Areas. We
next sought to determine if mature DCs were also infiltrat-
ing tumor tissue. Mature DCs were characterized by ex-
pression of CD83 and DC-Lamp. Although no CD831 cells
were found in 9/9 samples of normal breast tissue, CD831
mature DCs could be identified in 20/32 breast cancer
samples (the threshold for positivity was established arbi-
trarily for a density greater than or equal to two cells per
high power field). Most interestingly, mature DCs were lo-
cated in the peritumoral areas surrounding but not pene-
trating the beds of carcinoma cells (Fig. 1 b). The number
of CD831 mature DCs per high power field (4003)
ranged from 0 to 28 cells, with mean and median numbers
5 and 6, respectively (Table II). Staining for DC-Lamp, a
highly specific marker of mature DCs (26), confirmed the
peritumoral localization of mature DCs in breast cancer tis-
sue (Fig. 1 b). Compared with immature DCs residing within
the tumor bed, the mature DC-Lamp1 DCs found in the
peritumoral area displayed intense MHC class II labeling
mostly located at the cell periphery, attesting to cell surface
expression (Fig. 2 b).
Table II. In Situ Phenotype of DCs in Breast Carcinoma Tissue
Patient CD1a DCGM4 CD83 CD11c HLA-DR CD80 CD86
1 2 0 1 30 45 15 26
21 0 1 4 3 8 7 2 2 0 3 2
3 17 20 8 24 14 11 25
4 3 0 0 40 51 24 26
5 4 0 2 24 40 20 22
66 3 1 1 5 0 8 0 1 5 1 4
7 18 11 2 17 52 13 20
8 1 0 0 30 40 14 36
9 2 0 7 12 14 9 14
10 8 13 5 24 22 4 7
11 6 4 4 55 45 18 26
12 11 3 0 60 58 26 23
13 2 2 1 29 60 8 17
14 12 7 0 30 42 9 16
15 7 5 2 50 32 8 20
16 11 3 1 45 50 13 40
17 48 12 10 39 53 27 42
18 30 32 28 53 63 22 37
19 41 17 7 52 59 32 43
20 10 0 0 24 22 15 10
21 3 2 0 45 50 25 14
22 6 0 2 40 12 18 22
23 10 0 8 35 20 15 15
24 7 0 12 50 20 15 26
25 1 1 5 40 30 18 11
26 4 0 15 25 25 15 23
27 18 10 1 20 30 20 16
28 45 10 6 35 40 26 32
29 5 3 3 58 52 20 32
30 2 1 2 68 71 18 24
31 21 15 0 46 38 20 14
32 28 17 1 50 49 29 32
Mean 6 SD 12 6 13 6 6 85  6 6 39 6 14 42 6 18 18 6 7 24 6 10
Values represent the number of cells labeled with antibody recognizing an indicated marker/high power field.1422 Mature Dendritic Cell Infiltration in Breast Carcinoma
The antibodies recognizing HLA-DR, CD80, and CD86
did not reveal DC compartmentalization because their ex-
pression pattern also includes macrophages that are scat-
tered throughout the breast cancer tissue in all studied sam-
ples. Similarly, CD11c1 labeling, found earlier to define DCs
within germinal centers (9), was present in all 32 tumor
samples without any apparent compartmentalization.
T Cells Colocalize with Mature DCs in Some Breast Carcinoma
Samples. Because mature DCs can normally be found only
in secondary lymphoid organs where they closely interact
with Ag-specific T cells, we next analyzed the T cell distri-
bution and activation pattern in breast carcinoma samples.
In 19 evaluated samples, CD31 T cells infiltrated peritumoral
areas, where they could be seen either scattered throughout
the area in close proximity to tumor cells or clustered (Fig. 1).
Double stainings for CD4 and CD83 demonstrated, in three
out of five studied cases, T cells clustered around mature
DCs in the peritumoral areas (Fig. 1 c). The majority of in-
filtrating T cells (70–75%) were CD31CD81, and a frac-
tion of them (,10%) displayed the early activation markers
CD69 and CD25. No T cell proliferation could be seen, as
judged by labeling with Ki67 antibody (not shown).
Mature DCs Bind Selectively to Peritumoral Areas. We as-
sessed the capacity of fluorochrome-labeled DCs to adhere
to frozen sections of breast cancer tissue in an adapted ver-
sion of the Stamper-Woodruff assay measuring binding of
lymphocytes to endothelium (31). As illustrated in Fig. 3,
immature DCs adhere selectively to the tumor cells and
spread upon binding. In contrast, mature DCs, generated
by CD40 ligation, adhere selectively to the peritumoral ar-
eas, thus confirming the pattern of in situ DC localization
(Fig. 3). Both immature and mature DCs adhere to tissue
sections that contain infiltrating DCs, as detected immuno-
histochemically (Table III). Labeled Raji cells did not to
bind to any of the tumor sections, further demonstrating
the specificity of DC binding.
Figure 2. In breast carcinoma tissue, im-
mature DCs express intracellular MHC class
II vesicles, whereas mature DCs express sur-
face MHC class II molecules. Immunofluo-
rescence staining on frozen sections evalu-
ated by confocal microscopy as described in
the Fig. 1 legend. (a) MHC class II mole-
cules, stained with directly coupled L243
mAb (green), mostly reside in intracellular
compartments in DCs identified by labeling
with CD1a mAb (red) within the tumor
bed. (b) Mature DCs, identified with lyso-
some resident marker DC-Lamp (red), ex-
press high numbers of cell surface MHC
class II molecules (green). This pattern has
been observed in three out of three ana-
lyzed samples.
Figure 3. Immature DCs selectively adhere to tumor cells, whereas mature DCs adhere to tumor parenchyma. (a) Schematic presentation of DC bind-
ing experiments using a modified version of the Woodruff-Stamper assay. DCs generated in vitro from either CD341 HPCs or blood monocytes were
FITC labeled and overlaid (105 cells) on frozen sections of breast carcinoma tissue. After 60 min at 208C and stringent washing, the sections were labeled
with anticytokeratin antibody (Texas [TX]Red). (b) Immature CD341, HPC–derived, sorted CD1a1 DCs adhere selectively to cytokeratin-labeled breast
cancer cells (203; patient 17). (c) Mature DCs, generated from blood monocytes and activated by CD40 ligation, adhere selectively to tumor stroma
(203; patient 11). Representative of six experiments using breast carcinoma tissue from six patients.1423 Bell et al.
Immature DC Infiltration Is Associated with High Expression
of MIP3a by Tumor Cells. Recent studies demonstrated the
expression of CCR6 on immature DCs (32), and the DC
ligand MIP3a was identified in epithelia, the site of resi-
dence of immature LCs (33). We thus analyzed the expres-
sion pattern of MIP3a within breast tumors. First, reverse
transcriptase (RT)-PCR analysis of whole breast cancer
samples indicated the presence of MIP3a mRNA, whereas
no MIP3a mRNA could be amplified from normal breast
tissue (Fig. 4 a). PCR analysis of MIP3b expression showed
lack of mRNA in the breast cancer tissue, whereas MIP3b
was expressed in the tonsillar tissue (Fig. 4 a).
Immunohistochemical analysis of seven breast cancer
samples (Table IV) further demonstrated the expression of
MIP3a protein by the majority of tumor cells and colocal-
ization of immature DCs and MIP3a-producing cells (Fig. 4,
b–d). Two normal breast specimens did not express the
MIP3a protein. Thus, accumulation of immature DCs
within the tumor bed may be dependent on the expression
of MIP3a by tumor cells.
Discussion
Herein we demonstrate the unique compartmentaliza-
tion of immature and mature DCs within breast carcinoma
tissue. 32/32 tumor samples displayed variable immature DC
infiltration. This compartmentalization was further confirmed
by the binding of in vitro–generated immature DCs to tumor
beds. Tumor-infiltrating immature DCs were heterogeneous,
and two populations could be identified, both CD1a1
Langerin1 LCs and non-Langerhans, CD1a1Langerin2 cells.
Because dermal (interstitial) DCs were found in vitro and
in vivo to express CD1a but not Langerin, we currently
Table III. Binding of Immature and Mature DCs to Breast Cancer 
Tissue Sections
Patient
Immature DCs Mature DCs
Tumor Stroma Tumor Stroma
24 16 6 1.5 1 6 0.6 1 6 1.5 21 6 2
29 6 6 2.5 0.7 6 16  6 3 39 6 18
11 ND ND 0.7 6 1 14 6 6
Quantitation of binding of immature and mature DCs to breast carci-
noma tissue sections. Values are mean 6 SD of adherent cells per 0.2
mm2 measured within three individual areas in the tissue section.
Figure 4. Breast carcinoma cells express MIP3a mRNA and protein. (a) Expression of MIP3a and
MIP3b was determined by RT-PCR using total RNA extracted from fresh breast carcinoma tissue.
Immunohistochemistry staining with a control (b) or anti-MIP3a (c) antibody reveals specific MIP3a
staining of breast carcinoma cells (203; patient 28). Representative pattern of MIP3a expression from
seven samples. (d) CD1a-labeled immature DCs (blue) colocalize with MIP3a-expressing breast cancer
cells (red) (patient 28).
Table IV. In Situ DC Phenotype and MIP3a Expression in 
Breast Carcinoma
Patient CD1a1 CD831 MIP3a staining
16 11 1 111
25 1 5 11
28 45 6 111
29 5 3 2
30 2 2 1
31 21 0 111
32 28 1 11
Numbers of CD1a- or CD83-expressing cells per high power field.1424 Mature Dendritic Cell Infiltration in Breast Carcinoma
conclude that CD1a1Langerin2 tumor-infiltrating DCs may
be intDCs. The pathophysiological significance of this het-
erogeneity remains to be established. Earlier studies revealed
that intDCs generated in vitro from CD341 HPCs display
(a) more potent phagocytic activity than LCs and (b) a unique
ability to induce differentiation of naive B cells (6, 7).
As a hallmark of immature phenotype, DCs infiltrating
the tumor bed expressed compartmentalized intracellular
MHC class II molecules (34–36). This subcellular distribu-
tion of MHC class II molecules changed dramatically in
mature peritumoral DCs, where most of the class II mole-
cules were relocated to the cell surface.
The observed numbers of immature CD1a1 DCs in the
tumor microenvironment appeared much higher than in
normal breast epithelium, suggesting increased homing and
infiltration. This may be best explained by the high levels
of intratumoral MIP3a, a chemokine that was recently
shown to specifically attract immature DCs (33, 37–39) and
is now found to be expressed within the tumor epithelium.
The immunohistochemistry analysis with anti-MIP3a is
not, unfortunately, precise enough to allow a correlation
between the amount of MIP3a within the tumor cells and
the numbers of infiltrating immature DCs. The increased
numbers of immature DCs could reflect a transient stage
due to the high in and out migration or the sequestering of
immature DCs within the tumor tissue.
Perhaps the most important finding is the presence, in
20/32 breast carcinoma samples, of mature DCs that were
located specifically within the peritumoral areas. This strik-
ing compartmentalization was further confirmed by the
binding of in vitro–generated mature DCs to peritumoral
areas. This indicates that stromal factors are determining the
DC adherence. Because mature DCs are only observed in
lymphoid organs, where they closely interact with T cells,
it is tempting to consider that their presence within the tu-
mor tissue reflects an ongoing immune response, possibly
tumor specific. These mature DCs present within the tu-
mor tissue could derive from any of the currently defined
DC subsets discussed above. Unfortunately, the tools avail-
able now do not allow us to determine the subset origin.
Because of recent data showing the role of DC subsets in
Th1/Th2 polarization and the induction of different classes
of immune response (8), the determination of the origin
and immunocompetence of mature, tumor-associated DCs
will be of great importance to our understanding of the de-
velopment of tumor immunity.
The limited number of relatively heterogeneous breast
cancer tissue samples analyzed to date does not allow us to
establish a prognostic significance of the infiltration of tu-
mor with immature or mature DCs. Such determination will
require the analysis of a large number of samples in prospec-
tive or retrospective studies. Unfortunately, currently avail-
able CD1a and DC-Lamp antibodies do not permit analysis
of paraffin-embedded archival material. Therefore, we are
now evaluating alternative methodologies for the determi-
nation of DC phenotype in archival material and initiating
a prospective analysis using frozen tissue samples.
Our observations open a new avenue in tumor immunol-
ogy. A thorough analysis of the DC system within tumors
will provide clues critical to understanding the development
of tumor immunity.
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